Relay Therapeutics Q3 EPS $(0.54) Beats $(0.83) Estimate, Sales $25.20M Up From $344.00K YoY
Portfolio Pulse from bharat@benzinga.com
Relay Therapeutics reported Q3 losses of $(0.54) per share, beating the analyst consensus estimate of $(0.83) by 34.94%. This is a 28.95% increase over losses from the same period last year. The company also reported $25.20 million in sales, a 7.23K% increase YoY.
November 02, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relay Therapeutics reported better than expected Q3 results with a significant increase in sales YoY.
Relay Therapeutics reported a smaller loss than expected and a significant increase in sales. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100